HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Chattem

This article was originally published in The Rose Sheet

Executive Summary

Sales of firm's Bull Frog sun care line soared 92% in the third quarter, driven by "increased distribution and display programs and reduced returns," Chattem reports Sept. 17. Selsun blue sales were up 6%, and domestic factory shipments have grown from approximately $20 mil. in 2001 to a projected $34 mil. this year, Chattem states. Bull Frog, Selsun blue, Gold Bond, Icy Hot, Aspercreme and Pamprin led a 12% sales increase to $66.1 mil. in the quarter, which was offset by a 41% decline in Dexatrim sales. Operating income excluding charges related to settlement of litigation concerning Dexatrim with phenylpropanolamine (PPA) was $16.8 mil., up 6%, and net income excluding litigation settlement charges advanced 36% to $9.3 mil. Firm also announces it will introduce a number of new products under Bull Frog, pHisoderm and Gold Bond brands...

You may also be interested in...



Bayer's Job Cuts And Flat 2021 Sales Outlook Disappoint

Licensing agreements and bolt-on acquisitions to strengthen its R&D pipeline are still in Bayer’s sights as the COVID-19 pandemic and currency devaluations have led to the need for job cuts and substantial cost savings at the big pharma company.

Global Medtech Guidance Tracker: September 2020

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Twenty-seven guidance documents have been posted on the tracker since its last update.

Still Looking For A Cancer Vaccine Breakthrough, Roche Signs $200m Vaccibody Deal

Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.

UsernamePublicRestriction

Register

ID1132090

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel